

Declaration on Corporate Governance

The actions of the executive and supervisory bodies of CompuGroup Medical SE & Co. KGaA (hereinafter also referred to as "CompuGroup Medical" or the "Company" and together with its affiliates the "CompuGroup Medical Group") are governed by the principles of responsible and good corporate governance. In the following, please find the report of the Managing Directors of the Company's General Partner, CompuGroup Medical Management SE, and the Supervisory Board of CompuGroup Medical on corporate governance in accordance with principle 22 of the German Corporate Governance Code and in accordance with sections 289f, 315d German Commercial Code (HGB).

1. Declaration of Conformity with the German Corporate Governance Code

Declaration by the General Partner and by the Supervisory Board of
CompuGroup Medical SE & Co. KGaA
on the recommendations of the
government commission on the German corporate governance code (Regierungskommission
Deutscher Corporate Governance Kodex)
pursuant to section 161 German Stock Corporation Act (AktG)

I. Preamble

The Managing Directors of the General Partner and the Supervisory Board of CompuGroup Medical SE & Co. KGaA last issued a Declaration of Compliance pursuant to Section 161 (1) German Stock Corporation Act (AktG) on January 19, 2021.

The German Corporate Governance Code (the “Code”) is tailored to companies in the legal form of a stock corporation (AG) or a European stock corporation (SE) and does not take into account the specifics of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA). Many of the Code’s recommendations can therefore not be applied or can only be applied in a modified form to CompuGroup Medical SE & Co. KGaA. In this context, the following aspects in particular must be taken into account:

1. Management

Many recommendations in the Code are directed at the management board. However, in contrast to stock corporations like an AG or a SE with a two-tier structure, a partnership limited by shares (KGaA) does not have a management board. In a partnership limited by shares (KGaA), the general partner takes on the responsibilities of the management board. The sole General Partner of CompuGroup Medical SE & Co. KGaA is CompuGroup Medical Management SE, which manages the business of CompuGroup Medical SE & Co. KGaA and represents it. CompuGroup Medical Management SE has a one-tier structure. In accordance with this structure, the management of the SE is performed by a single board, the Administrative Board. The Administrative Board manages CompuGroup Medical Management SE, defines the fundamental strategy of its activities and supervises its implementation by the Managing Directors. The Managing Directors conduct the operating business of the SE and represent the SE in and out of court. Accordingly, the Managing Directors also manage the business of CompuGroup Medical SE & Co. KGaA.

2. Supervisory Board

Some of the recommendations in the Code concerning the supervisory board do not take into account the legal specifics of a partnership limited by shares (KGaA). In contrast to the supervisory board of an AG and a SE with a two-tier structure, the supervisory board of a partnership limited by shares (KGaA) has neither the responsibility for the appointment and removal of the members of the management board nor the authority to determine the remuneration for the

members of the management board. Furthermore, the supervisory board of a partnership limited by shares (KGaA) does not have authority to determine approval requirements with regard to certain management measures.

3. Annual General Meeting

The annual general meeting of a partnership limited by shares (KGaA) basically has the same rights as the annual general meeting of an AG. In addition, it decides on the adoption of the annual financial statements of the company. In contrast to the legal form of an AG, some resolutions of the annual general meeting (e.g. the adoption of the annual financial statements) require the consent of the general partner.

II. Declaration of Compliance:

The Managing Directors of the General Partner and the Supervisory Board of CompuGroup Medical SE & Co. KGaA declare that the recommendations of the German Corporate Governance Code 2020 (“DCGC 2020”) published by the Federal Ministry of Justice in the official section of the Federal Gazette on March 20, 2020 have been and will continue to be complied with in the period since the last declaration of compliance issued on January 19, 2021, taking into account the structural particularities of a partnership limited by shares (KGaA), with the exception of the recommendations stated below for the reasons and in the periods stated therein:

a) Recommendations B.1 to B.5

Recommendations B.1 to B.5 concern the composition of the management board and the criteria that the supervisory board should observe when appointing members to the management board. The management of a partnership limited by shares (KGaA), however, is by law the responsibility of the general partner. The supervisory board of a partnership limited by shares (KGaA) does not have any personnel authority and is therefore unable to influence the appointment of the board members of the general partner. The Supervisory Board does not appoint the Managing Directors or the members of the Administrative Board. Rather, the Managing Directors are appointed by the Administrative Board of the General Partner. The members of the Administrative Board are in turn appointed by the Annual General Meeting of the General Partner. As a result, recommendations B.1 to B.5 are not relevant for CompuGroup Medical SE & Co. KGaA. Only as a matter of precaution, we also declare a deviation from these recommendations.

b) Recommendation C.1, sentences 1 to 4

The Supervisory Board of CompuGroup Medical SE & Co. KGaA adopted specific targets for its composition and a competence profile on February 22, 2021. In doing so, the Supervisory Board also paid attention to diversity. The status of implementation will be published in the next corporate governance statement.

c) Recommendation C.2

Recommendation C.2 states that an age limit should be specified for members of the supervisory board and disclosed in the corporate governance statement. The Company

does not believe setting a fixed age limit is a suitable criterion with regard to the appointment of members to its Supervisory Board. Instead, the Company takes the age of a suitable candidate into account on an individual basis in the selection process as one component in the overall assessment of the person's expertise, experience and performance ability.

d) Recommendation D.5

Recommendation D.5 states that the supervisory board should form a nomination committee, composed exclusively of shareholder representatives, which proposes suitable candidates to the supervisory board for its proposal of candidates to be appointed by the annual general meeting. All current shareholder representatives were appointed with effect as of June 18, 2020 when the change of legal form became effective by its registration in the commercial register. The term of their appointment ends with the Annual General Meeting that resolves on the discharge for the fiscal year 2024. The Supervisory Board therefore sees currently no need to form a nomination committee. With regard to future vacancies, the Supervisory Board considers the ad-hoc formation of a temporary nomination committee.

e) Recommendation E.3

Recommendation E.3 states that members of the management board should only assume sideline activities, especially supervisory board mandates outside the enterprise, with the approval of the supervisory board. CompuGroup Medical SE & Co. KGaA does not have a management board. Nevertheless, in the interest of the greatest possible compliance with the recommendations of the Code, it is stipulated that the Managing Directors may only assume sideline activities, especially supervisory board mandates outside the Group, with the consent of the Administrative Board of the General Partner.

f) Recommendations on the remuneration of the management board (G.1 to G.13, G.15 and G.16)

Recommendations G.1 to G.13, G.15 and G.16 DCGC 2020 contain detailed requirements that the supervisory board shall take into account when determining the remuneration of the management board. However, the Supervisory Board of CompuGroup Medical SE & Co. KGaA does not have the authority to determine the remuneration of the Managing Directors of the General Partner, so that the recommendations on the remuneration of the management board do not fit to CompuGroup Medical SE & Co. KGaA due to the corporate structure. The remuneration of the Managing Directors is rather determined by the Administrative Board of the General Partner. Only as a matter of precaution, we also declare a deviation from the aforementioned recommendations.

Notwithstanding this, for reasons of good corporate governance the Administrative Board of the General Partner adopted a remuneration system for the Managing Directors on March 2, 2021, which takes into account the relevant recommendations of the Code and was voluntarily submitted to the Annual General Meeting for approval. It was approved by the Annual General Meeting of the Company on May 19, 2021. The remuneration system applies to all new service contracts to be concluded with Managing Directors and to all contract extensions.

Koblenz, December 13, 2021

signed by Dr. Dirk Wössner (CEO)
(CFO)

signed by Michael Rauch

On behalf of the Managing Directors of the General Partner

signed by Philipp von Ilberg
(Chairman of the Supervisory Board)

On behalf of the Supervisory Board of CompuGroup Medical SE & Co. KGaA

2. Reference to the Company website

The remuneration report for the past fiscal year and the independent auditor's report pursuant to section 162 German Stock Corporation Act (AktG) as well as the most recent resolution regarding remuneration pursuant to section 113 (3) AktG are publicly available on the Company's website at www.cgm.com/ir. The provision stated in section 87a German Stock Corporation Act (AktG) on the establishment of a management board remuneration system does not apply directly to CompuGroup Medical due to its legal form as a partnership limited by shares (KGaA). However, for reasons of good corporate governance and transparency, the Company nevertheless decided to voluntarily base its remuneration system for the Managing Directors on section 87a AktG. This remuneration system is also publicly available on the website at www.cgm.com/ir.

3. Corporate Governance Statement

CompuGroup Medical is aware of its important role as a responsible member of society. Since 1987, today's CompuGroup Medical has been working on the vision of a digitalized healthcare system and sees itself as a forerunner in digitized medical care. As envisaged by our founder Frank Gotthardt – "Nobody should suffer or die just because at some point medical information was missing" – we help healthcare professionals and patients use medical information for the benefit of all parties involved, wherever and whenever. Our products and solutions ensure a perfect working environment for our customers. We confront the daily challenging issues in the healthcare sector by applying our products, platforms and many years of market experience, and we guarantee constant availability of medical and administrative data with the aim of providing patients and their relatives with the most efficient and optimal care possible. We do this while observing high standards of data protection and the fail-safety for the systems provided. Our products and solutions comply not only with applicable laws and regulations but also with our commitment to ethical and social responsibility. Ethical guidelines are firmly anchored in our corporate culture and our Code of Ethics and apply to all employees of the CompuGroup Medical Group as well as to business partners acting on behalf of the company. We also expect our suppliers and partners to adhere to a code of ethics that is consistent with our ethical values. The Code of Ethics of the CompuGroup Medical Group is available on our corporate website at www.cgm.com/ir.

4. Description of the mode of operation of CompuGroup Medical Management SE including its Managing Directors and Administrative Board

CompuGroup Medical's legal form is a German partnership limited by shares (KGaA). One of the core principles of German company law is commonly a two-tier management system with an executive body and a supervisory board as the monitoring body. The legal form of a KGaA differs here as its business activities are managed by a General Partner. At CompuGroup Medical, CompuGroup Medical Management SE assumes the role of the management body as General Partner in accordance with the Articles of Association. The Supervisory Board of CompuGroup Medical supervises the management of the General Partner in accordance with the powers assigned to it by law and the Articles of Association. CompuGroup Medical has also established the additional voluntary corporate body of the Joint Committee ("Joint Committee"). Half of this committee consists of members of the Supervisory Board of CompuGroup Medical, the other half consists of members nominated by CompuGroup Medical Management SE.

CompuGroup Medical Management SE is a European stock corporation (SE) with a one-tier structure. CompuGroup Medical Management SE is represented by its corporate bodies: the general meeting, the administrative board ("Administrative Board") and the managing directors ("Managing Directors"). CompuGroup Medical Management SE – represented by its Managing Directors – carries out the business activities of CompuGroup Medical with the due care and diligence of a prudent and conscientious manager and is committed to the corporate interests of CompuGroup Medical.

The sole shareholder of CompuGroup Medical Management SE is GT 1 Vermögensverwaltung GmbH, with its registered office in Koblenz. The share capital of GT 1 Vermögensverwaltung GmbH is held by Frank Gotthardt (99.36 %) and Professor Dr. Daniel Gotthardt (0.64 %). Both are also members of the Administrative Board of CompuGroup Medical Management SE.

In its function as General Partner, CompuGroup Medical Management SE does not hold an equity interest in CompuGroup Medical and does not participate in the earnings and assets of the Company. The General Partner is reimbursed by CompuGroup Medical for all expenses incurred in connection with the management of the Company's business activities, including the remuneration of the members of its corporate bodies. As stipulated by the Articles of Association of CompuGroup Medical, the Company pays the General Partner an annual remuneration in the amount of 4 % of its share capital, which is independent of the Company's profits and losses, in addition to reimbursing its expenses for the management of the Company and the assumption of liability. This remuneration reflects

in particular the liability risk assumed by CompuGroup Medical Management SE as the General Partner of CompuGroup Medical.

a. The Managing Directors of CompuGroup Medical Management SE

The Managing Directors manage the business activities of CompuGroup Medical Management SE and, by virtue of their capacity as General Partner of CompuGroup Medical, thus indirectly also the business of the Company. In this capacity, they implement the general guidelines and requirements set up by the Administrative Board. The Managing Directors manage the business activities with the due care and diligence of a prudent and conscientious manager in accordance with applicable law, the German Corporate Governance Code – to the extent the General Partner and the Supervisory Board have decided to comply with the individual recommendations –, the Articles of Association, the Rules of Procedure for the Managing Directors and the Directives of the Administrative Board.

In accordance with the Rules of Procedure, the following allocation of responsibilities applies to the Managing Directors:

- **Dr. Dirk Wössner (CEO):**

The **Chief Executive Officer**(CEO) is responsible for coordinating all areas of responsibility of the Managing Directors. It is his responsibility to ensure that all business units of the CompuGroup Medical Group are uniformly aligned to the objectives determined by the Administrative Board. The CEO represents the Company and the CompuGroup Medical Group to the public. He can delegate CompuGroup Medical Group's financial market communication, in whole or in part, to the Chief Financial Officer.

The CEO is responsible for cooperating with the Administrative Board. He informs the Administrative Board immediately of any extraordinary events of particular significance that occur at the level of the General Partner, the Company or the CompuGroup Medical Group. In particular, the CEO is responsible for the business performance of the CompuGroup Medical Group. He has senior responsibility for M&A transactions, brand management and communication. The CEO also heads CompuGroup Medical Group's Central IT, Legal & Compliance as well as Global Human Resources including organizational development, cultural work, responsibility for sustainability and corporate social responsibility as well as central services and is thus the head of the CompuGroup Medical Group's Labor and Social Affairs department.

- **Frank Brecher (CTO):**

The **Chief Technology Officer** (CTO) acts as a cross-function across all business units and defines the overarching product and software architecture. He supports the business units by defining, guiding, auditing, providing advice and training for development processes and tools and the development organization. The objective of his organization is to optimize product development throughout the CompuGroup Medical Group. At the same time, he is responsible for the provision of suitable near and offshore development services. The CTO has product responsibility for the Clickdoc and LIFE platforms.

- **Angela Mazza Teufer:**

. The Managing Director is responsible for the CompuGroup Medical Group's revenue and earnings in the segments Ambulatory Information Systems for doctors in the DACH region and the telematics infrastructure in Germany. This also extended her responsibility to the expansion of the above segments, including the development and marketing of related services and products.

- **Emmanuele Mugnani:**

The Director has revenue and profit responsibility for the CompuGroup Medical Group's Physician Information Systems businesses in Africa and Europe, excluding the DACH region, and for the CompuGroup Medical Group's Pharmacies and Dental Information Systems businesses worldwide. Thus, he is also responsible for the further development of the aforementioned areas incl. the development and marketing of associated services and products.

- **Dr. Eckart Pech:**

The Managing Director is responsible for revenue and earnings in the Consumer & Health Management Information Services (CHS) segment of the CompuGroup Medical Group. This segment comprises business with consumer, with population and data management as well as the health connectivity services business, including the CGM LIFE platform and add-on products that are not allocated to a product line, the global development of eHealth platforms for connectivity and communication, and the development and marketing of related services. He is therefore also responsible for the development of above mentioned business areas of CompuGroup Medical Group on a global scale,

including the development and marketing of related services and products.

- **Michael Rauch (CFO):**

The **Chief Financial Officer** (CFO) is responsible for managing accounting, controlling, internal and external audits, liquidity planning and investor relations in the CompuGroup Medical Group. He is responsible for preparing all financial statements required as well as fulfilling related disclosure requirements. Furthermore, he is in charge of coordinating the budget planning. The CFO is also in charge of defining, introducing and maintaining optimal, efficient business processes within all areas of the CompuGroup Medical Group by introducing state-of-the-art efficiency and process management in line with the OneGroup approach. Together with his team, he advises and trains the top management levels of the CompuGroup Medical Group regarding the continuous optimization of processes and measures to increase efficiency. In addition, the CFO is responsible for requesting and assessing profitability analyses for capital spending programs, as well as requesting and assessing associated budgets. In order to be able to carry out these tasks, the CFO has the relevant information rights and direct access to R&D Controlling.

- **Hannes Reichl:**

The Director is responsible for revenue and earnings in the CompuGroup Medical Group's Hospital Information Systems segment (comprising information systems for hospitals and care facilities, solutions for rehabilitation facilities and laboratory information systems). This also extends his responsibility to the development of the above segment on a global scale, including the development and marketing of related services and products.

The Managing Directors have introduced a Disclosure Committee and an M&A Committee. The Disclosure Committee currently consists of three members: the CFO (Chairman), the Global General Counsel and the Head of Investor Relations. The Disclosure Committee is responsible for the review and compliance with disclosure requirements under capital market law, in particular for the review of potential insider information issues and disclosure requirements, the review of potential postponements of publications and decision-making on the postponement as well as the preparation of the required documentation. The M&A committee reviews the proposals for investment prepared by the relevant business units, in particular including the assessment of economic conditions and the contract documentation submitted, and proposes investment projects to the Managing Directors.

Regardless of the above-described division of responsibilities, the principle of overall responsibility for the management of CompuGroup Medical's business lies with the Managing Directors.

In regular meetings (usually once a week), the Managing Directors jointly discuss and decide upon a broad spectrum of topics from day-to-day business to strategic orientation.

In accordance with the Rules of Procedure for the Managing Directors, certain transactions or measures – for example, the resolution on larger acquisitions or the determination of the annual budget – require the prior approval of the Administrative Board of CompuGroup Medical Management SE. In addition, the Articles of Association of CompuGroup Medical stipulate that transactions with a major impact as well as decisions regarding annual corporate, investment and financial master plans require the approval of the Joint Committee of the Company.

The Rules of Procedure furthermore provide detailed specifications with regard to general cooperation and coordination with the Administrative Board as well as communication from the Managing Directors to the Administrative Board, sideline activities of Managing Directors that require approval by the Administrative Board as well as regulations concerning the handling of conflicts of interest and the passing of resolutions. Conflicts of interest must be disclosed without undue delay to the Administrative Board, and the remaining Managing Directors must be informed thereof. Resolutions of the Managing Directors are made by simple majority of the votes cast unless otherwise provided by law or the Articles of Association. If there is a tied vote, the CEO has the casting vote.

There is currently no age limit for Managing Directors. The age of the Managing Directors currently ranges between 45 and 53 years, with an average of 50 years.

b. The Administrative Board of CompuGroup Medical Management SE

CompuGroup Medical Management SE has a one-tier structure with an Administrative Board, which comprises five members as stipulated by the Articles of Association. The members are: Frank Gotthardt (Chairman), Dr. Klaus Esser (Vice Chairman), Stefanie Peters, Professor Dr. Daniel Gotthardt and Dr. Dirk Wössner. Dr. Dirk Wössner is also CEO of CompuGroup Medical Management SE.

The members of the Administrative Board are elected by the annual general meeting of CompuGroup Medical Management SE. The Administrative Board has not currently set a rigid age limit for its members. The age of the members of the Administrative Board currently ranges between 48 and 74 years, with an average of 60 years.

The Administrative Board manages CompuGroup Medical Management SE in accordance with the legal provisions, the Articles of Association of CompuGroup Medical Management SE and its Rules of Procedure. It sets the general course of its business activities and supervises their implementation. The Administrative Board appoints and supervises the Managing Directors and has adopted Rules of Procedure governing their actions (article 7 (2) of the Articles of Association of CompuGroup Medical Management SE). The Rules of Procedure for the Administrative Board of CompuGroup Medical Management SE contain detailed provisions on meetings of the Administrative Board; these are presided over by the Chairman or, if the Chairman is unable to attend, by the Vice Chairman, and must be recorded in minutes. The Rules of Procedure also provide that the Administrative Board is represented by its Chairman.

The Managing Directors, represented by the CEO, inform the Administrative Board at regular intervals and in a timely manner about the relevant issues of business development, the risk situation as well as significant deviations from budget planning and from the targets of CompuGroup Medical and the CompuGroup Medical Group. The Administrative Board is informed in a timely manner of any extraordinary events that are of significance for CompuGroup Medical Management SE and/or the CompuGroup Medical Group.

The Administrative Board convenes at least once a quarter for its regular meeting. So far, the Administrative Board has not yet made use of its option to form committees.

5. Description of the operating principles and composition of the Supervisory Board of CompuGroup Medical SE & Co. KGaA

The main responsibility of the Supervisory Board of CompuGroup Medical is to monitor the management of the Company by CompuGroup Medical Management SE as General Partner. This duty is performed on the basis of the legal provisions, taking into account the recommendations of the German Corporate Governance Code – with the exception of the deviations stated in the Declaration of Compliance –, the Articles of Association of CompuGroup Medical and the Rules of Procedure for the Supervisory Board. The Rules of Procedure, which include more detailed provisions on the convening and holding of Supervisory Board meetings and the formation of committees, can be viewed on the CompuGroup Medical website at www.cgm.com/ir.

The Supervisory Board consists of twelve members, of whom six are elected by the Annual General Meeting of the Company and six by the employees in accordance with the provisions of the German Codetermination Act (MitbestG) of May 4, 1976. The current employee representatives in office were appointed on September 30, 2021 by the employees of CompuGroup Medical who were entitled to vote. There is currently no rigid age limit for members of the Supervisory Board. The age of the members of the Supervisory Board currently ranges between 32 and 73 years, with an average of 51 years. Currently, 92 % of Supervisory Board members are younger than 60.

Succession planning for members of the Supervisory Board is currently not relevant, as the term of office of the shareholder representatives runs until the Annual General Meeting in 2025. Therefore, the Supervisory Board has not seen any need to form a Nomination Committee to date. The Chairman of the Supervisory Board would temporarily take over the tasks related to the selection process for potential candidates and would coordinate with other members of the shareholder representatives on an ad hoc basis if it became necessary to discuss the succession of individual members until a Nomination Committee is formed. If needed, a Nomination Committee composed of shareholder representatives would then be formed at short notice.

In its search for potential candidates for the Supervisory Board, the Supervisory Board is guided by its competence and diversity concept. Specialized recruitment consultants may also be used.

The Supervisory Board has come to the conclusion that in accordance with recommendations C.6/C.7 of the German Corporate Governance Code, the Supervisory Board shall comprise at least four members on the shareholder side, i.e. more than half of the shareholder representatives, who are independent of the Company and its General Partner

(cf. recommendation C.7 German Corporate Governance Code) and at least four members who are independent of a controlling shareholder (cf. recommendation C.9 German Corporate Governance Code). In the opinion of the Supervisory Board and its shareholder representatives, all shareholder representatives on the Supervisory Board currently meet the independence criteria of recommendations C.6, C. 7 and C.9 of the German Corporate Governance Code.

In the opinion of the Supervisory Board, the requirements of section 100 (5) of the German Stock Corporation Act (AktG) are met, as at least one Supervisory Board member has expertise in the field of accounting and at least one other Supervisory Board member has expertise in the field of auditing, and the members as a whole are familiar with the sector in which the Company operates.

New Supervisory Board members get insight from the Company at the beginning of their term of office concerning the business model, the corporate strategy of the CompuGroup Medical Group and the legal particularities of the corporate governance structure pertaining to the legal form of CompuGroup Medical SE & Co. KGaA with a one-tier general partner (CompuGroup Medical Management SE). The responsible Managing Directors and their teams, other senior managers of the CompuGroup Medical Group as well as external legal advisors also support the onboarding process. In the past fiscal year, the aforementioned measures and some training courses were carried out for the new Supervisory Board members following the election of employee representatives.

At least two regular Supervisory Board meetings are held in each calendar half-year, which are usually attended by the Managing Directors on behalf of the General Partner. In each ordinary meeting, the Supervisory Board always has the option to discuss agenda topics without the attendance of the representatives of the General Partner.

The CEO and the CFO regularly report to the Supervisory Board on the general development of business activities and the financial situation of the CompuGroup Medical Group and its key business units. In addition and as required, the Managing Directors report on the development of business activities in the areas of their responsibility and the further development of the business units concerned. The Supervisory Board may ask the Managing Directors to provide more information on the items on the agenda and intended resolutions.

In accordance with the provisions of section 27 German Codetermination Act (MitbestG), the Supervisory Board elects a Chairman and a Vice Chairman. The Chairman of the Supervisory Board coordinates its work. He or she chairs the meetings and represents the Supervisory Board to the public. Furthermore, the Chairman explains the Report of the Supervisory Board to the shareholders, in particular at the Annual General Meeting. Resolutions of the Supervisory Board are adopted by a simple majority of the votes cast, unless otherwise provided by law. If a vote of the Supervisory Board is tied, and a new vote on the same subject also results in a tie, the Chairman of the Supervisory Board has the casting vote. The same applies when the votes are submitted in writing. The Vice Chairman is not entitled to the casting vote – even if they stand in for the Chairman of the Supervisory Board.

The Supervisory Board formed an Audit Committee. The Audit Committee generally consists of four members with one half representatives of the shareholders and one half representatives of the employees. In fiscal year 2021, the members of the Audit Committee on the shareholder side were Matthias Störmer (Chairman) and Philipp von Ilberg. The employee representatives on the Audit Committee were Ursula Keller (until September 30, 2021), Andreas Wiese (from February 22, 2021 to September 30, 2021), Thomas Veith (until January 15, 2021), Ayfer Basal (from October 28, 2021) and Lars Johnke (from October 28, 2021). The Committee focuses on the audit of the financial statements, the monitoring of the financial reporting process, the effectiveness of the internal control system, the risk management system and the internal audit system, compliance, the preliminary audit of the annual and consolidated financial statements, the preliminary audit of the non-financial reporting, the assessment of the quality of the audit of the financial statements, and the approval for the provision of any non-audit services by the auditor. The Committee discusses the half-year financial reports and interim reports with the Managing Directors prior to their publication. The auditor regularly attends the meetings of the Audit Committee to ensure an exchange of information with the Audit Committee. In this context, there is always opportunity for consultation even without representatives of the General Partner being present.

The Supervisory Board reviews regularly, usually every two years, how effectively the Supervisory Board in general and its committees in particular perform their duties. The Supervisory Board of the Company last reviewed the effectiveness of its activities in December 2021 by conducting a standardized survey among the members of the Supervisory Board and openly discussing related findings in the Supervisory Board meeting.

The Supervisory Board's detailed report to the Annual General Meeting, which is included in the respective Annual Report, provides insight into the key topics handled by the Supervisory Board in the fiscal year under review. It is available on the corporate website at <https://www.cgm.com/ir>.

On February 16, 2022, the Supervisory Board updated its concrete objectives for the composition and competence profile of the overall body.

A list of the members of the Supervisory Board, its committees and the Joint Committee, including information on the length of service on these bodies is provided in the appendix to this declaration. For the shareholder representatives, the list states whether they are classed as independent (within the meaning of the recommendations of the German Corporate Governance Code) by the Supervisory Board, and in particular by its shareholder side.

6. Cooperation of the Supervisory Board and the General Partner

The cooperation of the Supervisory Board and the General Partner is based on the two-tier management principle as legally prescribed for the structure of a partnership limited by shares (KGaA). An essential aspect of the two-tier structure is the separation of the management and executive responsibilities assigned to the General Partner by law from the supervisory duties assigned to the Supervisory Board. Furthermore, the cooperation is based on the Rules of Procedure, which the relevant bodies have issued that also take into account the specific aspects of the legal form of a partnership limited by shares (KGaA), and (with regard to the General Partner) of a one-tier European stock corporation (CompuGroup Medical Management SE).

The General Partner, represented by the Managing Directors and especially the CEO and the CFO, keeps the Supervisory Board informed about the relevant issues of business development, the risk situation as well as significant deviations from the budget planning and the targets of the Company and the CompuGroup Medical Group at regular intervals and in a timely manner. The Supervisory Board is informed in a timely manner of any extraordinary events that are of significance for the Company and/or the CompuGroup Medical Group. Between the regular meetings, the Chairman of the Supervisory Board and the CEO of the General Partner, who is also a member of the Administrative Board of CompuGroup Medical Management SE, maintain a dialog on the topics relevant to the Company.

7. The Joint Committee of CompuGroup Medical SE & Co. KGaA

The Company established a Joint Committee, which consists of six members. Three of the members of the Joint Committee are delegated to the Joint Committee by the General Partner, and three of the members of the Joint Committee are delegated to the Joint Committee by the Supervisory Board of the Company (consisting of two shareholder representatives and one employee representative). The General Partner appoints one of the members it delegates to the Joint Committee as Chairman.

Article 18 of the Articles of Association of CompuGroup Medical stipulates that certain topics require the approval of the Joint Committee of the Company. In addition to the annual corporate, investment and financial planning, this pertains in particular to transactions with related parties, certain company acquisitions and other transactions if they exceed certain significant thresholds set out in the Articles of Association.

Article 19 of the Articles of Association of CompuGroup Medical sets out the procedures for meetings and resolutions of the Joint Committee. Resolutions of the Joint Committee are adopted by a simple majority of the votes cast. If a vote is tied and a new vote on the same subject also results in a tie, the Chairman of the Joint Committee has the casting vote. The Rules of Procedure of the Joint Committee contain more detailed provisions on the convening and holding of meetings of the Joint Committee and also the chairing of meetings. In accordance with the Rules of Procedure, the Joint Committee is convened if a decision on a transaction requiring approval becomes necessary.

8. Gender representation in the Supervisory Board and at management levels

As a listed company to which the German Codetermination Act (MitbestG) applies, the Supervisory Board of CompuGroup Medical must be composed of at least 30 % women and at least 30 % men in accordance with section 278 (3) and section 96 (2) German Stock Corporation Act (AktG). In principle, the Supervisory Board as a whole may comply with the minimum quota. However, the representatives of the shareholders have objected to the compliance based on the body as a whole. For this reason, the minimum gender quota currently has to be met separately by both the shareholder representatives and the employee representatives. The legal requirements concerning the gender quota are currently met by both the shareholder and the employee sides.

The Supervisory Board of the Company's legal predecessor, CompuGroup Medical SE, had retained the target for the share of women on the Management Board at zero % on March 16, 2017. At the time the change of legal form took effect on June 18, 2020, the status was in line with the objective. As CompuGroup Medical no longer has a Management Board, there was no need to set a new target. With CompuGroup Medical Management SE neither being listed nor subject to codetermination, the General Partner is not obliged to comply with either the legal requirements for gender quotas in corporate bodies nor the requirement to set fixed composition targets for the share

of women in corporate bodies or the top management levels below the executive level.

It is disputed, to which extent the German Management Positions Act (FÜPoG II) applies to the legal form of the partnership limited by shares (KGaA). If the Act applies, the requirement that at least one woman and at least one man must be managing directors would apply to new appointments from August 1, 2022. This requirement is currently already met.

The Administrative Board of CompuGroup Medical Management SE has set itself a voluntary target of 30 % for the share of women among the Managing Directors of CompuGroup Medical Management SE, which it wants to achieve by December 31, 2025. The share of women among the executive directors is currently 14.3 %

The share of women in the Administrative Board is 20 %. With regard to the Administrative Board of CompuGroup Medical Management SE, the Administrative Board has set itself the voluntary goal to include at least one woman. This target is currently met.

In accordance with section 76 (4) German Stock Corporation Act (AktG), the Management Board of the Company's predecessor last discussed the targets for the share of women working in positions at the management levels below the Management Board in August 2018 and, taking into account the specific situation of the Company, determined the following: The target for the share of women was set at 30 %. The deadline for achieving the target was set at July 31, 2023. As at December 31, 2021, the share of women at the two management levels below the top management level of the General Partner was 30.0 %.

Group HR, led by the Chairman of the Managing Directors and CEO, is responsible for Corporate Responsibility and non-financial reporting across the Group. A dedicated position was created for this purpose, which manages and implements concepts and measures on a centralized basis.

9. Diversity at CompuGroup Medical SE & Co. KGaA

Owing to the Company's international and interdisciplinary focus on diverse stakeholders in the healthcare market in many different countries and cultures around the world, diversity actually comes natural to CompuGroup Medical. This applies with regard to an adequate representation of both genders as well as the greatest possible diversity, especially with regard to cultures, religions and ethnic backgrounds. Drawing on the diverse professional backgrounds and experience of its employees and members of corporate bodies is an important factor for the Company.

Upon its inception, the Supervisory Board of CompuGroup Medical discussed and defined the concrete objectives for its composition as well as a corresponding competence profile, and prepared a diversity concept that is suitable for the Company, which was adopted on February 22, 2021 and last updated on 16 February 2022.

With regard to the appointment of the Managing Directors, the Administrative Board takes into account not only professional aspects but also the objective of a heterogeneous composition of this corporate body in order to be able to do justice to the target markets and business activities of the Company and the CompuGroup Medical Group. The Administrative Board of CompuGroup Medical Management SE has set itself a voluntary target of 30 % for the share of women among the Managing Directors of CompuGroup Medical Management SE, which it wants to achieve by December 31, 2025. In order to avoid formal restrictions with regard to the appointment of Managing Directors, the Administrative Board of the General Partner has not established a formal diversity concept based on section 289f (2) no. 6 German Commercial Code (HGB) so far.

10. Competence profile and diversity concept of the Supervisory Board

a. Objectives for the composition of the Supervisory Board

The Supervisory Board of CompuGroup Medical SE & Co. KGaA shall be composed in a way that its members as a whole have the knowledge, skills and professional experience required to properly perform the Supervisory Board duties. The proposal to the Annual General Meeting of candidates for the election to the Supervisory Board is to be based on their professional knowledge and experience, integrity, willingness to perform, independence and personality, which allow them to successfully perform the tasks of a member of the Supervisory Board in a software company with international operations. Moreover, the following aspects should also be taken into account:

- Personality and integrity: The members of the Supervisory Board must be reliable and possess the knowledge and experience needed to perform the duties of a Supervisory Board member conscientiously and on their own responsibility.
- Independence: On the side of the shareholder representatives, at least four members shall be independent within the meaning of recommendations C.6 to C.9 German Corporate Governance Code of CompuGroup Medical SE & Co. KGaA, the General Partner, its corporate bodies and a controlling shareholder.
- Conflicts of interest: The Supervisory Board shall not include any persons who hold a position on a corporate body or a consulting function at a major competitor of the Company, or who have a personal relationship with a major competitor. In addition, the Supervisory Board shall not include more than two former members of the Managing Directors of the General Partner or of the Management Board of the legal predecessor of the Company.
- Available time: Each member of the Supervisory Board ensures that it can afford the expected time required to properly exercise the Supervisory Board mandate. When accepting further mandates, the statutory restrictions on mandates and the recommendations of the German Corporate Governance Code must be complied with.

b. Competence profile for the overall body

The Supervisory Board as a whole must have the necessary expertise and competences required to perform its duties effectively and to be able to assess the business and activities conducted by the Company. This can only be achieved if the members of the Supervisory Board as a whole are familiar with the sector in which the Company operates. The Supervisory Board regards the following competences, experience and knowledge as significant for the Supervisory Board as a whole:

- experience in leading companies, organizations, associations and networks;
- adequate knowledge of the capital market;
- adequate knowledge of finance, accounting, controlling and bookkeeping;
- at least one member with expertise in information technology and digitization;
- at least one member with healthcare expertise;
- at least one member with expertise in the areas of law and compliance;
- at least one member of the Supervisory Board must have expertise in the field of accounting within the meaning of section 100 (5) German Stock Corporation Act (AktG), and
- at least one other member of the Supervisory Board must have expertise in the field of auditing as defined in section 100 (5) German Stock Corporation Act (AktG);
- at least one member with expertise in the areas of HR and society as well as corporate and social responsibility.

In its composition, the Supervisory Board also strives for diversity with regard to age, origin, internationality, different educational and professional backgrounds, as well as an adequate participation of both genders. In accordance with the requirements of section 96 (2) German Stock Corporation Act (AktG), the Supervisory Board must be composed of at least 30 % women and at least 30 % men. In accordance with section 96 (2) sentence 3 German Stock Corporation Act (AktG), the shareholder representatives have resolved that this share must be achieved by both sides, the shareholder side and the employee side.

In addition, each member of the Supervisory Board shall meet the general personal requirements set out in item 1 above.

c. Diversity concept for the Supervisory Board

The Supervisory Board of CompuGroup Medical SE & Co. KGaA is of the firm opinion that a heterogeneous composition of the corporate body contributes to the Supervisory Board working effectively and is therefore in the best interest of the Company. When defining concrete objectives for the composition of the Supervisory Board and the competence profile for the overall body, the Supervisory Board therefore took diversity aspects into account. Age, gender, educational and professional background and international expertise/internationality in particular are the factors governing the goals of the Supervisory Board with respect to its composition:

- The Supervisory Board generally strives for a mixed age structure. At least 30 % of the members of the Supervisory Board should be below 60 years of age.
- In accordance with the requirements of section 96 (2) German Stock Corporation Act (AktG), the Supervisory Board must be composed of at least 30 % women and at least 30 % men.
- The composition of the Supervisory Board should be such that the members complement each other in terms of their professional profiles and professional and personal experience in order for the Supervisory Board to cover a broad spectrum of experience and knowledge.
- At least 30 % of the members of the Supervisory Board have international experience based on either where they are from or their professional background.

The Supervisory Board will take these aspects into account when making its proposals to the Annual General Meeting for future elections or re-elections of shareholder representatives to the Supervisory Board.

There were no changes in the composition of the Supervisory Board on the shareholder representatives' side in the past 2021 fiscal year. Such a change is also not foreseeable at present. Therefore, the implementation status of the competence profile has not changed since the last declaration.

The employee representatives elected their representatives to the Supervisory Board on September 30, 2021 in accordance with statutory requirements. Six members were elected: three women and three men. One member belongs to the Group's senior management team, two members are representatives of trade unions represented in the Group.

11. Limited shareholders and the Annual General Meeting of CompuGroup Medical SE & Co. KGaA

CompuGroup Medical has issued solely registered ordinary shares. Shareholders who are listed in the Company's share register at a specific cut-off date have the right to attend the Company's Annual General Meeting in compliance with the conditions set out by the relevant legal provisions and the Articles of Association in order to exercise their shareholder rights. In accordance with the Articles of Association, the Chairman of the Supervisory Board of CompuGroup Medical generally presides over the Annual General Meeting. He or she also determines the order of deliberations and voting, as well as the form of voting. The Chairman of the Supervisory Board may also impose reasonable restrictions on the right to ask questions and speak. In accordance with German regulations (German Act Concerning Measures Under the Law of Companies, Cooperative Societies, Associations, Foundations and Commonhold Property to Combat the Effects of the COVID-19 Pandemic), it is currently also allowed to hold the Annual General Meeting as an exclusively virtual meeting because of the ongoing COVID-19 pandemic. In this exceptional case, certain shareholders' rights can only be exercised to a limited extent.

The powers of the Annual General Meeting of the Company are generally in line with the common powers of annual general meetings of stock corporations or a European stock corporation, insofar as the corresponding powers are regulated by stock corporation law regulations. Instead of the actions of a management board being formally approved, the General Meeting of a KGaA formally approves the actions taken by the General Partner (section 285 (1) no. 2 German Stock Corporation Act (AktG)). In addition to the powers resulting from the German Stock Corporation Act (AktG), for a KGaA, the powers resulting from partnership law are also relevant. The Articles of Association of CompuGroup Medical provide that, in deviation from legal provisions, the General Meeting has no right of objection in the case of extraordinary management measures of the General Partner. The Articles of Association stipulate instead that certain extraordinary management measures have to be approved by the Joint Committee. In addition, the German Stock Corporation Act (AktG) grants powers to the General Meeting of a KGaA on the basis of special legislative provisions. This includes the adoption of the annual financial statements (section 286 (1) sentence 1 German Stock Corporation Act (AktG)), while in CompuGroup Medical's previous legal form, this had been the responsibility of the Supervisory Board. The resolution of the Annual General Meeting on the adoption of the annual financial statements requires the approval of the General Partner (section 286 (1) sentence 2 German Stock Corporation Act (AktG)).

The exercise of voting rights by the limited shareholders of CompuGroup Medical is likewise governed by the provisions of stock corporation law (section 278 (3) German Stock Corporation Act (AktG)). If the General Partner holds shares in the KGaA that entitle the General Partner to vote at the General Meeting, this voting right is subject to certain restrictions (section 285 (1) German Stock Corporation Act (AktG)). In this regard, the General Partner (which includes, according to prevailing opinion, in any case the shareholders controlling it and its management) is prohibited from casting a vote on the election and dismissal of members of the Supervisory Board, granting the formal approval to the actions taken by the General Partner and the members of the Supervisory Board, the appointment of special auditors, the assertion of claims for damages and the waiver of claims for damages, and the election of the auditor of the annual financial statements. These voting restrictions take account of a possible conflict of interest on the part of the General Partner.

With respect to convening the General Meeting, the provisions applicable to a stock corporation (sections 278 (3), 283 no. 6 German Stock Corporation Act (AktG)) also apply without restriction to a partnership limited by shares (KGaA). However, in contrast to the SE, the maximum period permitted under the German Stock Corporation Act (AktG) for holding the ordinary Annual General Meeting of a KGaA is eight months (sections 278 (3), 175 (1) sentence 2 German Stock Corporation Act (AktG)).

In the General Meeting of a KGaA, the required majority is generally based on the same provisions that are applicable to a stock corporation (section 278 (3) German Stock Corporation Act (AktG)). According to section 179 (2) sentence 2 German Stock Corporation Act (AktG) in conjunction with article 26 (3) of the Articles of Association, resolutions of the General Meeting amending the Articles of Association are adopted by a simple majority of the votes cast and by a simple majority of the share capital represented when the resolution is adopted, unless mandatory statutory provisions require a larger majority. Moreover, article 10 (8) sentence 2 of the Articles of Association of CompuGroup Medical provides that, in specific cases stated therein, the resolution on the change of legal form of CompuGroup Medical into an SE only requires a simple majority of the votes cast.

Certain resolutions of the General Meeting of a KGaA also require the approval of the General Partner (section 285

(2) sentence 1 German Stock Corporation Act (AktG)). In a limited partnership, this requirement of approval applies to all matters for which the consent of both the General Partner and the limited shareholders is required (section 285 (2) sentence 1 German Stock Corporation Act (AktG)). The requirement of approval pertains to, for example, resolutions in connection with capital measures, intercompany agreements, transformation measures (such as mergers or changes of legal form) and the dissolution of the Company.

12. Accounting and audits of financial statements

CompuGroup Medical prepares its consolidated financial statements and its interim consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union. After they were prepared by the General Partner, the financial statements are audited by the auditor appointed by the Annual General Meeting. Based on the audit reports and the documentation of the consolidated financial statements, the Supervisory Board approves the consolidated financial statements, if necessary, after a preliminary review by its Audit Committee. Following the legal regulations, the Annual General Meeting of CompuGroup Medical is competent to resolve the adoption of the annual financial statements. This resolution requires the consent of CompuGroup Medical Management SE as General Partner. Interim reports and half-year reports are discussed by the General Partner and the Audit Committee prior to their publication.

13. Control and management system and basic principles of the compliance system

The internal control system of CompuGroup Medical and the CompuGroup Medical Group is based on Group-wide regulations and core business processes, in which standardized procedures are defined and guidelines for Group-wide risk management are provided. All of the individual business units permanently monitor and assess risks and communicate both the risks and the corresponding countermeasures initiated to the central risk management department of CompuGroup Medical, which is located at corporate headquarters. Risk reporting is an integral part of the regular reporting and controlling processes. In addition, the Audit Committee of the Supervisory Board is regularly provided with consolidated risk reports. Details on risk management are presented in the risk report within the management report. In addition, the report on the accounting-related internal control and risk management system required by the German Accounting Law Modernization Act (BilMoG) can be found in the (Group) management report.

Compliance with the regulations and process flows defined for the CompuGroup Medical Group is reviewed at regular intervals by the Internal Audit department. These reviews focus on key aspects of the audit as coordinated with the Audit Committee.

Responsible handling of entrepreneurial risks is one of the principles of good corporate governance. The management of CompuGroup Medical has Group-wide and Company-specific reporting and control systems at their disposal, which ensure that these risks are recorded, evaluated and managed. The systems are continuously refined and adapted to the changing framework conditions and reviewed and evaluated by the auditor of the annual financial statements (section 317 (4) German Commercial Code (HGB). In 2019, the existing system was replaced by a more efficient application of Monte Carlo simulation. This application enables Risk Management to prospectively conduct additional analyses or evaluate additional risk indicators. Furthermore, against the background of the new version of IDW PS 340, which is to be applied from 2021, procedural changes were made in order to be able to map the requirements at an early stage.

The Managing Directors regularly inform the Supervisory Board about existing risks and their development. The Audit Committee is primarily concerned with monitoring the accounting process, including reporting, the effectiveness of the internal control system, risk management, compliance, and auditing.

Details on CompuGroup Medical's risk management are presented in the Combined Management Report under the Risk Report section. In addition, the report on the accounting-related internal control and risk management system required by the German Accounting Law Modernization Act (BilMoG) is included in the Combined Management Report.

CompuGroup Medical stands against all forms of corruption, bribery and trading in influence, and actively strives to avoid such conduct in the CompuGroup Medical Group's business activities. In its publicly available Code of Ethics applicable to all participants in the supply chain, CompuGroup Medical prohibits offering, distributing or accepting bribes or kickbacks of any kind along with the use of other ways and channels for granting an unjustified advantage to customers, representatives, contractors, suppliers and their employees, or government officials. CompuGroup Medical also prohibits its employees from giving bribes or kickbacks to customers, representatives, contractors, suppliers and their employees, or government officials, or accepting such bribes or kickbacks from these individuals in

order to create an advantage for themselves or their families, friends, partners or acquaintances.

The controls instituted by CompuGroup Medical comprise regular self-assessments for senior management. Additional controls are exercised by way of internal and external audits, for example, as part of fraud and management override of control reporting. A Group-wide Legal & Compliance Affairs unit reporting to the CEO was established to reinforce CompuGroup Medical's clear position both in-house and externally. CompuGroup Medical is continuously improving its Group-wide compliance management system. In fiscal year 2021 this area was strengthened by establishing a central Group Compliance Officer function.

An internal whistleblower system is in place at CompuGroup Medical, which provides employees and third parties with the opportunity to anonymously report suspicious incidents relating to unethical, illegal, fraudulent or undesirable conduct in activities of the CompuGroup Medical Group. The whistleblower system guarantees confidentiality so that individuals who make a report can do so without fear or intimidation, disadvantage or retribution. Information on the whistleblower system and contacts is available to all employees in the intranet. Valid information is reported immediately to the General Partner and the Supervisory Board. In the reporting year, no reportable incidents were known or reported by individuals within or outside of the Company. The effectiveness and design of the whistleblower system are continuously reviewed and adapted to the new legal requirements. In December 2021, the whistleblower system was thus converted to a new multilingual, digital system.

CompuGroup Medical strives for compliance with the Company's principles described in the Code of Ethics concerning relationships with external business partners in the contractual agreements, partnerships and collaborations entered into. The Company achieves this through diligently reviewing planned agreements, partnerships and collaborations prior to the signing of contracts and by careful selection of external business partners.

Compliance with the Company's principles described in CompuGroup Medical's Code of Ethics by employees and management is ensured in particular by informing employees of these when they begin working at the Company. Employees are also obligated to comply with material principles as part of their employment contracts.

The Code of Ethics is signed by the Managing Directors and is published on the CompuGroup Medical website. The Code of Ethics is reviewed once a year. Amendments require the approval of the General Partner.

CompuGroup Medical considers respect for human rights to be an integral part of its responsibility as a company with worldwide operations. This is why we are committed not only to strictly adhering to all applicable statutory provisions but also to the staunch defense of human rights in our sphere of influence. Given the industry in which we operate, CompuGroup Medical employs highly qualified IT employees. Human rights issues are categorized as immaterial, because this constitutes a minimal operational risk. In order to underscore this issue, CompuGroup Medical has made an explicit commitment on responsibility to society in its generally applicable Code of Ethics. Compliance with these standards is required not only of all employees but also of all suppliers, business partners, consultants or third parties working on behalf of CompuGroup Medical Group.

14. Transparency

CompuGroup Medical attaches great importance to the uniform, comprehensive and timely dissemination of information. Reporting on the business situation and results of CompuGroup Medical is provided in the annual report, the quarterly disclosures, the six-month reports, at the annual Investor and Analyst Conference and in regular conference calls. In addition, information is provided in the form of press releases and ad hoc disclosures, in addition to other mandatory publications to the extent required by law. All reports and announcements can be viewed online at www.cgm.com/ir in the Investor Relations section. CompuGroup Medical has issued a Group-wide insider trading policy and uses an electronic tool to maintain lists of its senior managers and insider projects. The relevant persons have been or are informed of their legal obligations and sanctions. In addition to that, CompuGroup Medical has identified further persons (beyond the listed group of persons directly affected in accordance with legal provisions) who are subject to a trading ban with shares and derivatives of CompuGroup Medical in a defined period of 30 days prior to the publication of financial figures.

15. Shareholdings of the members of corporate bodies of the General Partner and the members of the Company's Supervisory Board

On the basis of the information available to the Company, the members of corporate bodies currently have the following shareholdings:

Supervisory Board of CompuGroup Medical SE & Co. KGaA:

Professor Dr. Martin Köhrmann	8,000 shares (approx. 0.01 %)
Dr. Michael Fuchs	1,500 shares (approx. 0.00 %)
Matthias Störmer	1,300 shares (approx. 0.00 %)
Adelheid Hegemann	34 shares (approx. 0.00 %)
Stefan Weinmann	25 shares (approx. 0.00 %)

Administrative Board of CompuGroup Medical Management SE:

Frank Gotthardt	17,910,804 (approx. 33.33 %)
Professor Dr. Daniel Gotthardt	3,571,711 shares (approx. 6.65 %)
Dr. Klaus Esser	140,000 shares (approx. 0.26 %)
Dr. Dirk Wössner	4,750 shares (approx. 0.01 %)
Stefanie Peters	400 shares (approx. 0.00 %)

Managing Directors of CompuGroup Medical Management SE

Michael Rauch	5,000 shares (approx. 0.01 %)
Dr. Dirk Wössner	4,750 shares (approx. 0.01 %)
Hannes Reichl	2,500 shares (approx. 0.00 %)
Frank Brecher	1,284 shares (approx. 0.00 %)
Dr. Eckart Pech	2,000 shares (approx. 0.00 %)
Emanuele Mugnani	0 shares (0.00 %)
Angela Mazza Teufer	0 shares (0.00 %)

Appendix: List of the members of the Supervisory Board and its committees (as at February 16, 2022)

Philipp von Ilberg^{1 2 3}(from June 18, 2020)

Managing Director of Mayer Sitzmöbel Verwaltungs-GmbH, General Partner of Mayer Sitzmöbel GmbH & Co.

KG, Redwitz

Place of residence: Bamberg

(Chairman, from June 18, 2020)

Dr. Michael Fuchs^{1 2} (from June 18, 2020)

Self-employed Management Consultant, Koblenz

Place of residence: Koblenz

Dr. Ulrike Handel¹(from June 18, 2020)

Self-employed Management Consultant, Hamburg

Place of residence: Hamburg

Professor Dr. Martin Köhrmann¹ (from June 18, 2020)

Deputy Director of the Department of Neurology at Essen University Hospital

Place of residence: Essen

Matthias Störmer^{1 3} (from June 18, 2020)

Self-employed Management Consultant, Frankfurt

Place of residence: Frankfurt

Dr. Bettina Volkens¹ (from June 18, 2020)

Self-employed Lawyer, Königstein

Place of residence: Königstein

Ayfer Basal^{3 4} (from September 30, 2021) Quality Assurance Professional at Lauer-Fischer GmbH, Fürth

Place of residence: Forchheim

Andrea Becker⁴ (July 3, 2020 to January 15, 2021)

Senior Product Architect at CompuGroup Medical Deutschland AG, Koblenz

Place of residence: Eitorf

Frank Betz^{2 4} (from September 30, 2021)

Marketing Professional at CGM Clinical Europe GmbH, Koblenz

Place of residence: Nuremberg

Claudia Frevel⁴ (from July 3, 2020 until September 30, 2021)

Project Manager at CGM IT Solutions Services GmbH, Koblenz

Place of residence: Treis-Karden

Adelheid Hegemann⁴ (from September 30, 2021) Senior Service Manager at CGM Clinical Deutschland GmbH,

Koblenz

Place of residence: Eberhardzell

Lars Johnke^{3 4} (from September 30, 2021) Trade Union Secretary, Industriegewerkschaft Metall, Munich

Place of residence: Aßling

Ursula Keller^{3 4} (from July 3, 2020 until September 30, 2021)

Communication Professional at CompuGroup Medical SE & Co. KGaA, Koblenz
Place of residence: Bergisch-Gladbach

Volker Kohl⁴ (from July 3, 2020 until September 30, 2021)
Senior Manager Development at CompuGroup Medical Deutschland AG, Koblenz
Place of residence: Dommershausen

Julia Mole⁴ (from January 15, 2021)
Trade Union Secretary, ver.di, Saarbruecken
Place of residence: Püttlingen

Sven Thomas Müller²⁴ (from July 3, 2020 until September 30, 2021)
Chief Information Officer of CompuGroup Medical SE & Co. KGaA, Koblenz
Place of residence: Nickenich
(Vice Chairman until September 30, 2021)

Thomas Veith³⁴ (from July 3, 2020 until January 15, 2021) Vice President CS Administration at CompuGroup Medical SE & Co. KGaA, Koblenz
Place of residence: Kratzenburg

Stefan Weinmann⁴⁵ (from September 30, 2021) Sales Professional at CGM Clinical Deutschland GmbH, Koblenz
Place of residence: Huglfing
(Vice Chairman as of October 28, 2021)

Andreas Wiese³⁴ (from January 15, 2021 until September 30, 2021)
Head of Department, ver.di (union), Mainz
Place of residence: Mainz

¹ Independent member on the shareholder side

² Member of the Joint Committee

³ Member of the Audit Committee

⁴ Employee representative

⁵ Vice Chairman